Combo of SGLT2 Inhibitor + GLP-1 RA Boosts Diabetes Survival

Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.
Medscape Medical News

source https://www.medscape.com/viewarticle/972230?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?